NASDAQ · FATE
Healthcare · Biotechnology
$2.52
Down-$0.20 (-7.35%)
Updated Aug 14, 2026, 9:50 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
FATE closed at $2.52 after 21 trading sessions, down 7.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $2.83 | $2.85 | $2.51 | $2.52 | 2.37M |
| Aug 12, 2026 | $2.75 | $2.805 | $2.69 | $2.72 | 1.23M |
| Aug 11, 2026 | $2.79 | $2.82 | $2.69 | $2.74 | 1.28M |
| Aug 10, 2026 | $2.85 | $2.85 | $2.74 | $2.76 | 1.95M |
| Aug 7, 2026 | $2.53 | $2.88 | $2.4833 | $2.80 | 4.02M |
| Aug 6, 2026 | $2.64 | $2.64 | $2.455 | $2.49 | 2.23M |
| Aug 5, 2026 | $2.615 | $2.675 | $2.56 | $2.60 | 3.39M |
| Aug 4, 2026 | $2.53 | $2.6899 | $2.412 | $2.57 | 6.44M |
| Aug 3, 2026 | $2.43 | $2.55 | $2.37 | $2.50 | 1.25M |
| Jul 31, 2026 | $2.51 | $2.555 | $2.39 | $2.45 | 1.46M |
| Jul 30, 2026 | $2.36 | $2.55 | $2.345 | $2.51 | 1.7M |
| Jul 29, 2026 | $2.33 | $2.43 | $2.26 | $2.36 | 1.08M |
| Jul 28, 2026 | $2.42 | $2.42 | $2.25 | $2.32 | 1.85M |
| Jul 27, 2026 | $2.49 | $2.52 | $2.39 | $2.43 | 564.08K |
| Jul 24, 2026 | $2.52 | $2.545 | $2.40 | $2.41 | 1.04M |
| Jul 23, 2026 | $2.57 | $2.61 | $2.47 | $2.52 | 1.64M |
| Jul 22, 2026 | $2.80 | $2.82 | $2.57 | $2.58 | 1.5M |
| Jul 21, 2026 | $2.84 | $2.86 | $2.78 | $2.83 | 1.14M |
| Jul 20, 2026 | $2.76 | $2.89 | $2.74 | $2.795 | 1.46M |
| Jul 17, 2026 | $2.66 | $2.935 | $2.60 | $2.78 | 1.69M |
| Jul 16, 2026 | $2.94 | $2.94 | $2.69 | $2.73 | 5.2M |
The latest Smart Investors Daily articles mentioning FATE.
FATE research
Company profile and research snapshot.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 31, 2025 | HC Wainwright & Co. | Buy | — |
| Oct 27, 2025 | Needham | Hold | — |
| Oct 27, 2025 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · May 13, 2026
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +10.87% and -25.77%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · May 13, 2026
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026 FDA selects FT819 into the CDRP (CMC Development and Readiness Pilot) program enabling early and enhanced communication with the FDA to ensure CMC readiness for accelerated clinical timelines Clinical data presented at Pediatric Rheumatology Symposium 2026 and Congress of
Finnhub · May 13, 2026
Fate Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 31.21 million compared to USD 37.62 million a...
Finnhub · May 13, 2026
SAN DIEGO — SAN DIEGO — Fate Therapeutics Inc. on Wednesday reported a loss of $31.2 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 26...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FATE.
